Type:200 metered Dose
Generic Name:Triamcinolone Acetonide Nasal prep
Manufacturer:Incepta Pharmaceuticals Ltd.
Price:৳200.00
Allergic rhinitis, Hay fever, Allergic and inflammatory responses.
Before using for first time, prime pump by releasing 5 sprays into air away from face If not used for >2 weeks, repeat priming by releasing 1 spray into air before using
Nasal Treatment and prophylaxis of allergic rhinitis Adult: The recommended starting dose is 220 mcg (4 sprays) into each nostril once daily. When the maximum benefit has been achieved and symptoms have been controlled, reducing the dose to 2 sprays (110 mcg) per day has been shown to be effective in maintaining control of the allergic rhinitis symptoms.
Nasal Treatment and prophylaxis of allergic rhinitis Children >12 years: Initially, 2 sprays (110 mcg) into each nostril once daily, maximum dose is 220 mcg (4 sprays) into each nostril once daily. When the maximum benefit has been achieved and symptoms have been controlled, reducing the dose to 2 sprays (110 mcg) per day has been shown to be effective in maintaining control of the allergic rhinitis symptoms. Children 6-12 years: The recommended starting dose is 2 sprays (110 mcg) per day given in each nostril once daily. Children not responding adequately to 110 mcg per day may use 220 mcg (4 sprays in each nostril) once daily. Once symptoms have been controlled, the dosage may be decreased to 2 sprays (110 mcg) once daily. Children 2-5 years of age: The recommended and maximum dose is 2 sprays (110 mcg) per day given in each nostril once daily.
Triamcinolone Acetonide is contraindicated in patients with a sensitivity to the active or inactive ingredients. Untreated systemic fungal, bacterial, viral or parasitic infection, hypersensitivity
Triamcinolone has mainly glucocorticoid activity. It suppresses the migration of polymorphonuclear leukocytes and reduces capillary permeability thereby decreasing inflammation.
Delay initiation of treatment in patients with recent nasal surgery, nasal trauma, nasal septum ulcers (until healing has occurred) Prolonged use may increase incidence of secondary infection Monitor for vision change, or with history of increased IOP, glaucoma, or cataracts Potential worsening of existing tuberculosis, fungal, bacterial, viral, or parasitic infections, or ocular herpes simplex More serious or fatal course of chickenpox or measles in susceptible patients Risk for hypercorticism and adrenal suppression with higher than normal doses Potential reduction of growth velocity in children Lactation: Unknown whether distributed in breast milk; exercise caution
1-10% Flu syndrome [children] (9%),Pharyngitis (5-8%),Headache [children] (6%),Bronchitis [children] (3%),Dyspepsia (3-5%),Tooth disorder [children] (3%),Epistaxis (3-5%),Excoriation [children] (3%),Increased cough (2- 8%),Upper abdominal pain [children] (5%),Diarrhea [children] (3%),Rash [children] (3%),Asthma [children] (3%),Rhinorrhea [children] (2%)
No significant drug interaction has been reported.
